Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
9.5100
-0.3000 (-3.06%)
NASDAQ · Last Trade: Nov 13th, 9:22 PM EST
Detailed Quote
Previous Close
9.810
Open
9.740
Bid
9.470
Ask
10.50
Day's Range
9.460 - 9.790
52 Week Range
8.930 - 30.36
Volume
110,276
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
99,367
Chart
About Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer patients. The company is particularly invested in the field of radiopharmaceuticals, which utilize radioactive isotopes to improve the precision of cancer treatment and diagnosis. Telix aims to address unmet medical needs by creating innovative solutions that enhance patient outcomes through its proprietary drug candidates, which are designed to target specific cancer types with minimal impact on healthy tissue. With an emphasis on oncology, Telix seeks to advance its product pipeline through clinical development and regulatory approval, ultimately working to transform the landscape of cancer care. Read More
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2026 to file a lead plaintiff motion.
LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2025 to file a lead plaintiff motion.
The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Telix investors under the federal securities laws.
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK).
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) that, for the first time, include the use of Telix’s investigational PET1 agent, TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), for molecular imaging of renal masses.
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA imaging and reimbursement gains.
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.
